PGM5-AS1表达和乳腺癌转移等恶性特征相关性的研究OA

Objective To investigate the expression of PGM5-AS1 in breast cancer with axillary lymph node metastasis and its effects on the proliferation,migration,and invasion of metastatic breast cancer cells.Methods qRT-PCR was used to detect the expression of PGM5-AS1 mRNA in 50 breast cancer tissues with axillary lymph node metastasis and corresponding adjacent tissues,metastatic breast cancer cell lines(MDA-MB-231 cells)and normal breast cell lines(MCF-10A cells).PGM5-AS1 was overexpressed in MDA-MB-231 cells using a recombinant plasmid.The changes in proliferation,migration,and invasion abilities of MDA-MB-231 cells after PGM5-AS1 overexpression were detected using the CCK8 assay,scratch wound assay,and Transwell invasion assay,respectively.Results In breast cancer with axillary lymph node metastasis and in metastatic MDA-MB-231 cells,the mRNA expression level of PGM5-AS1 was lower than that in the corresponding adjacent normal tissues and the normal breast MCF-10A cells(P＜0.05).after overexpression of PGM5-AS1,compared with PGM5-AS1 negative control group,the proliferation ability of MDA-MB-231 cells in PGM5-AS1 OE group was decreased,and the proliferation activity of MDA-MB-231 cells in overexpression group at 24,48,72 and 96 h after transfection was lower than that in PGM5-AS1 negative control group(P＜0.01).The scratch healing rate of PGM5-AS1 OE group was lower than that of PGM5-AS1 negative control group(P＜0.05).After overexpression of PGM5-AS1,cell invasion was reduced.Transwell invasion assay showed that the number of transmembrane cells in untreated MDA-MB-231 cells was(598.00±5.28),which was higher than(142.00±3.21)in PGM5-AS1 OE group,with statistical significance(P＜0.01).Conclusion In breast cancer with axillary lymph node metastasis,the expression level of PGM5-AS1 is upregulated and acts as a tumor suppressor gene.By upregulating the level of PGM5-AS1,the proliferation,migration,and invasion abilities of breast cancer cells can be effectively inhibited,making it a potential therapeutic target for breast cancer.